Telix Pharmaceuticals Sustainability Profile
Telix Pharmaceuticals Limited, commonly referred to as Telix, is a pioneering biopharmaceutical company headquartered in the United States, with significant operations across Europe and Asia-Pacific. Founded in 2015, Telix focuses on the development of innovative radiopharmaceuticals for the diagnosis and treatment of cancer, particularly in areas such as prostate and kidney cancers. The company’s core products, including its lead candidate TLX591 (also known as Illuccix), utilise advanced radiolabelled technologies that enhance precision in cancer imaging and therapy. Telix has established a strong market position, marked by notable achievements such as successful clinical trials and strategic partnerships that bolster its research and development capabilities. With a commitment to improving patient outcomes, Telix Pharmaceuticals is at the forefront of the evolving landscape of oncology therapeutics.
DitchCarbon Score
How does Telix Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Telix Pharmaceuticals's score of 25 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Telix Pharmaceuticals's reported carbon emissions
Telix Pharmaceuticals, headquartered in the US, currently does not report any specific carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As of now, Telix Pharmaceuticals has not inherited any emissions data from a parent company or related organisation, indicating that their climate commitments and emissions reporting are independent. Without specific emissions data or reduction initiatives, it is unclear how the company plans to address its carbon footprint or contribute to climate action within the pharmaceutical industry.
How Carbon Intensive is Telix Pharmaceuticals's Industry?
How Carbon Intensive is Telix Pharmaceuticals's Location?
Telix Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Telix Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
